Repositioning of the global epicentre of non-optimal cholesterol

Published: Nature
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health

Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight

Published: Diabetes Care
Date:
Authors: William I Sivitz 1 , Lawrence S Phillips 2 3 , Deborah J Wexler 4 , Stephen P Fortmann 5 , Anne W Camp 6 , Margaret Tiktin 7 , Magalys Perez 6 , Jacqueline Craig 8 , Priscilla A Hollander 9 , Andrea Cherrington 10 , Vanita R Aroda 11 , Meng Hee Tan 12 , Jonathan Krakoff 13 , Neda Rasouli 14 , Nicole M Butera 15 , Naji Younes 15 , GRADE Research Group
Abstract:
We evaluated the effect of optimizing metformin dosing on glycemia and body weight in type 2 diabetes.

Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring

Published: Diabetes Technology & Therapeutics
Date:
Authors: Mary E Larkin 1 , David M Nathan 1 , Ionut Bebu 2 , Heidi Krause-Steinrauf 2 , William H Herman 3 , John M Higgins 4 5 , Margaret Tiktin 6 , Robert M Cohen 7 , Claire Lund 2 , Richard M Bergenstal 8 , Mary L Johnson 8 , Valerie Arends 9 , GRADE Research Group
Abstract:
The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study has enrolled a racially and ethnically diverse population with type 2 diabetes, performed extensive phenotyping, and randomly assigned the participants to one of four second-line diabetes medications.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Published: The New England Journal of Medicine
Date:
Authors: Vlado Perkovic 1 , Meg J Jardine 1 , Bruce Neal 1 , Severine Bompoint 1 , Hiddo J L Heerspink 1 , David M Charytan 1 , Robert Edwards 1 , Rajiv Agarwal 1 , George Bakris 1 , Scott Bull 1 , Christopher P Cannon 1 , George Capuano 1 , Pei-Ling Chu 1 , Dick de Zeeuw 1 , Tom Greene 1 , Adeera Levin 1 , Carol Pollock 1 , David C Wheeler 1 , Yshai Yavin 1 , Hong Zhang 1 , Bernard Zinman 1 , Gary Meininger 1 , Barry M Brenner 1 , Kenneth W Mahaffey 1 , CREDENCE Trial Investigators
Abstract:
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.

Rising rural body-mass index is the main driver of the global obesity epidemic in adults

Published: Nature
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
Body-mass index (BMI) has increased steadily in most countries in parallel with a rise in the proportion of the population who live in cities1,2. This has led to a widely reported view that urbanization is one of the most important drivers of the global rise in obesity3-6

APPLICATION OF THE AACE/ACE ADVANCED FRAMEWORK FOR THE DIAGNOSIS OF OBESITY AND CARDIOMETABOLIC DISEASE STAGING IN A GENERAL POPULATION FROM 3 REGIONS OF VENEZUELA: THE VEMSOLS STUDY RESULTS

Published: Endocrine Practice
Date:
Authors: Ramfis Nieto-Martínez, Juan P González-Rivas, Eunice Ugel, Imperia Brajkovich, Alejandro Risquez, W Timothy Garvey, Jeffrey I Mechanick
Abstract:
To determine the prevalence of obesity according to the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) framework based on a complications-centric model with further application of the Cardiometabolic Disease Staging (CMDS) system in a Venezuelan population.

Are Eating Disorders Risk Factors for Type 2 Diabetes? A Systematic Review and Meta-analysis

Published: Current Diabetes Reports
Date:
Authors: Ramfis Nieto-Martínez 1 2 3 , Juan P González-Rivas 4 , José R Medina-Inojosa 5 , Hermes Florez 6 7
Abstract:
Eating disorders (ED) affect energy intake modifying body fat depots. Prior evidence suggests that binge eating disorder (BED) and bulimia nervosa (BN) could increase the risk for type 2 diabetes (T2D), while anorexia nervosa (AN) could reduce it.